

$R^5$  is H, alkyl, heteroalkyl, carbocyclic, or aralkyl;

B1  $R^6$  and  $R^7$  are independently H, alkyl, heteroalkyl, carbocyclic, heterocycloalkyl, aryl, heteroaryl, arylheterocycloalkyl which may be substituted with acyl groups, heteroalkylaryl which may be substituted with alkyl groups, aralkyl which may be substituted with acyl groups, or are members of the same heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl which may be substituted with alkylene groups, or aralkyl ring system, which may be substituted with -OH or -NH<sub>2</sub> groups; and

$R^8$  is H;

or a pharmaceutically acceptable salt, solvate, hydrate or formulation thereof.

4. (amended) Compounds according to Claim 1, wherein

X is H<sub>2</sub>N-C(=NH) - or HO-N=C(-NH<sub>2</sub>) - or R<sup>2</sup>OC(=O)-N=C(-NH<sub>2</sub>) - ,

$R^3$  is H,

B2  $R^4$  is H, methyl, hydroxymethyl, isopropyl, 2-imidazolyl, 3-pyrazolyl,

Ar is meta-phenylene,

$R^5$  is a small alkyl or an aralkyl group, and

$R^8$  is H.

5. (amended) Compounds according to Claim 1, wherein

X is H<sub>2</sub>N-C(=NH) - or HO-N=C(-NH<sub>2</sub>) - or R<sup>2</sup>OC(=O)-N=C(-NH<sub>2</sub>) - ,

$R^3$  is H,

$R^4$  is H, methyl, hydroxymethyl, 1,2-dihydroxyethyl, ethoxycarbonyl, isopropyl, cyclopropyl, 2-imidazolyl, 2-pyrrolyl, 3-pyrazolyl, 2-pyridyl, 4-methoxycarbonylphenyl,

Ar is meta-phenylene,

$R^5$  is a small alkyl or an aralkyl group,

$R^6$  is H and  $R^7$  is optionally substituted 1H-indol-3-yl-ethyl, 4-hydroxy-phenylethyl,

B2  
cyclohexyl, N-(2-methoxyphenyl)piperazinyl, 1,3-benzodioxol-5-ylmethyl, benzyl, phenethyl, 3,4-dimethoxyphenyl-1-ylmethyl, 2-methoxyphenyl-1-ylmethyl, 2-(4-morpholinyl)ethyl, 2-pyridinylethyl, 2-pyridinylpropyl, 3-pyridinylmethyl or R<sup>6</sup> and R<sup>7</sup> are part of a tetrahydroisoquinoline ring, a 4-thiomorpholine ring, a N-(2-methoxyphenyl)piperazine ring or a N-(4-methoxyphenyl)piperazine ring, and R<sup>8</sup> is H.

---

7. (amended) Compounds according to Claims 1 or 6, wherein

X is H<sub>2</sub>N-C(=NH) - or HO-N=C(-NH<sub>2</sub>) - or R<sup>2</sup>OC(=O) -N=C(-NH<sub>2</sub>) - ,

R<sup>3</sup> is H,

B3  
R<sup>4</sup> is H, methyl, hydroxymethyl, isopropyl, 2-imidazolyl, 3-pyrazolyl,

Ar is para-phenylmethylene group, and

R<sup>5</sup> is a small alkyl or an aralkyl group.

8. (amended) Compounds according to Claims 1 or 6, wherein

X is H<sub>2</sub>N-C(=NH) - or HO-N=C(-NH<sub>2</sub>) - or R<sup>2</sup>OC(=O) -N=C(-NH<sub>2</sub>) - ,

R<sup>3</sup> is H,

R<sup>4</sup> is H, methyl, hydroxymethyl, 1,2-dihydroxyethyl, ethoxycarbonyl, isopropyl, cyclopropyl, 2-imidazolyl, 2-pyrrolyl, 3-pyrazolyl, 3- or 4-phenoxy-phenyl, 1,3-benzodioxol-5-yl, 2-pyridyl, 4-methoxycarbonyl-phenyl,

Ar is para-phenylmethylene group,

R<sup>5</sup> is a small alkyl or an aralkyl group,

R<sup>6</sup> is H and R<sup>7</sup> is optionally substituted 1H-indol-3-yl-ethyl, 4-hydroxy-phenethyl, cyclohexyl, N-(2-methoxyphenyl)piperazinyl, 1,3-benzodioxol-5-ylmethyl, benzyl, phenethyl, 3,4-dimethoxyphenyl-1-ylmethyl, 2-methoxyphenyl-1-ylmethyl, 2-(4-morpholinyl)ethyl, 2-pyridinylethyl, 2-pyridinylpropyl, 3-pyridinylmethyl or R<sup>6</sup> and R<sup>7</sup> are part of a tetrahydroisoquinoline ring, a 4-thiomorpholine ring, a N-(2-methoxyphenyl)piperazine ring or a N-(4-methoxyphenyl)piperazine ring, and R<sup>8</sup> is H.